Brief: Essa Pharma Presents Updated Phase 1 Masofaniten Epi-7386 Clinical Data At The 2024 Asco Genitourinary Cancers Symposium

ESSA Pharma

25/01/2024 15:02

Jan 25 (Reuters) - 
  
    * ESSA PHARMA PRESENTS UPDATED PHASE 1 MASOFANITEN
(EPI-7386)
CLINICAL DATA AT THE 2024 ASCO GENITOURINARY CANCERS SYMPOSIUM
    * ESSA PHARMA INC - PHASE 2 DOSE EXPANSION CURRENTLY
UNDERWAY AT
RP2CDS OF MASOFANITEN 600 MG BID IN COMBINATION WITH
ENZALUTAMIDE 160 MG QD
    * ESSA PHARMA: COMBINATION OF MASOFANITEN PLUS ENZALUTAMIDE
CONTINUES TO BE WELL TOLERATED WITH DEEP, DURABLE REDUCTIONS IN
PSA IN PATIENTS WITH MCRPC
    * ESSA PHARMA INC: STUDY IS CURRENTLY ENROLLING AT
APPROXIMATELY
25 SITES IN USA, CANADA AND AUSTRALIA. EXPANSION TO EUROPEAN
SITES IS IN PROGRESS

Source text for Eikon:  ID:nPnbLP0B4a 
Further company coverage:  EPIX.O 

 ((Reuters.Briefs@thomsonreuters.com;))